Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression

Acute myeloid leukaemia (AML) is a genetically and clinically heterogeneous disease, characterized by expansion of undifferentiated myeloid precursor cells.1 Despite an increased understanding of the biology and therapeutic advances, the outcomes of AML patients remain unsatisfactory. Leukaemic cells express different antigens depending on their origin and their degree of maturation.2 Immunophenotypic assessment using flow cytometry (FCM) is...